6501 Sunitinib (SU) vs placebo for treatment of progressive, well- differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial

Raoul, J.L.; Niccoli, Patricia; Bang, Y-J.; Borbath, Ivan; Lombard‐Bohas, Catherine; Metrakos, Peter; Ai, Vinik; Lu, Dongrui R.; Blanckmeister, Carolyn A.; Raymond, Éric

doi:10.1016/s1359-6349(09)71223-6

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary results from this trial showed a median progression-free survival of 11.1 months in patients treated with sunitinib, compared with 5.5 months in patients treated with placebo (Hazard ratio 0.397, p<0.001). These preliminary data were presented at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain [9] and the ECCO/ESMO2009 in Berlin [10]. Adverse events were similar to those observed in other sunitinib studies and mainly consisted of neutropenia, hypertension, diarrhea, and hand-foot syndrome [11].…”

supporting

confidence: 53%

Sunitinib paves the way for targeted therapies in neuroendocrine tumors

et al. 2009

View full text Add to dashboard Cite

Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis.

show abstract

supporting

confidence: 53%

Sunitinib paves the way for targeted therapies in neuroendocrine tumors

et al. 2009

View full text Add to dashboard Cite

show abstract

“…• Sunitinib malate should be considered, because compared with placebo, it has been shown to improve pfs in progressive well-differentiated pancreatic islet cell tumours (level i) 50 .…”

mentioning

confidence: 99%

Eastern Canadian Colorectal Cancer Consensus Conference: Setting the Limits of Resectable Disease

et al. 2010

View full text Add to dashboard Cite

The annual Eastern Canadian Colorectal Cancer Consensus Conference was held in Montreal, Quebec, October 22–24, 2009. Health care professionals involved in the care of patients with colorectal cancer participated in presentation and discussion sessions for the purposes of developing the recommendations presented here. This consensus statement addresses current issues in the management colorectal cancer, such as the management of hepatic and pulmonary metastases, the role of monoclonal antibodies to the epidermal growth factor receptor, and the benefits and safety of chemotherapy in elderly patients. The management of gastrointestinal neuroendocrine tumours and gastric cancer are also discussed.

show abstract